RT Journal Article
SR Electronic
T1 Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.17.21257197
DO 10.1101/2021.05.17.21257197
A1 Muena, Nicolás A.
A1 García-Salum, Tamara
A1 Pardo-Roa, Catalina
A1 Serrano, Eileen F.
A1 Levican, Jorge
A1 Avendaño, María José
A1 Almonacid, Leonardo I.
A1 Valenzuela, Gonzalo
A1 Poblete, Estefany
A1 Strohmeier, Shirin
A1 Salinas, Erick
A1 Haslwanter, Denise
A1 Dieterle, Maria Eugenia
A1 Jangra, Rohit K.
A1 Chandran, Kartik
A1 González, Claudia
A1 Riquelme, Arnoldo
A1 Krammer, Florian
A1 Tischler, Nicole D.
A1 Medina, Rafael A.
YR 2021
UL http://medrxiv.org/content/early/2021/05/18/2021.05.17.21257197.abstract
AB The durability of circulating neutralizing antibody (nAb) responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and their boosting by vaccination remains to be defined. We show that outpatient and hospitalized SARS-CoV-2 seropositive individuals mount a robust neutralizing antibody (nAb) response that peaks at days 23 and 27 post-symptom onset, respectively. Although nAb titers remained higher in hospitalized patients, both study groups showed long-lasting nAb responses that can persist for up to 12 months after natural infection. These nAb responses in previously seropositive individuals can be significantly boosted through immunization with two doses of the CoronaVac (Sinovac) or one dose of the BNT162b2 (BioNTech/Pfizer) vaccines, suggesting a substantial induction of B cell memory responses. Noteworthy, three obese previously seropositive individuals failed to mount a booster response upon vaccination, warranting further studies in this population. Immunization of naïve individuals with two doses of the CoronaVac vaccine or one dose of the BNT162b2 vaccine elicited similar levels of nAbs compared to seropositive individuals 4.2 to 13.3 months post-infection with SARS-CoV-2. Thus, this preliminary evidence suggests that both, seropositive and naïve individuals, require two doses of CoronaVac to ensure the induction of robust nAb titers.Competing Interest StatementThe authors have declared no competing interest.Clinical Trial200829003Funding StatementWork in the Tischler Laboratory was partially funded by FONDECYT 1181799 and Programa de Apoyo a Centros con Financiamiento Basal 170004 grants from the Agencia Nacional de Investigacion y Desarrollo (ANID) of Chile. Work in the Medina Laboratory was based on protocols and the study set-up used for influenza virus established in part with the support of the PIA ACT 1408, FONDECYT 1161971 and 1212023 grants from the Agencia Nacional de Investigacion y Desarrollo (ANID) of Chile, the FLUOMICS Consortium (NIH-NIAD grant U19AI135972) and the Center for Research on Influenza Pathogenesis (CRIP), an NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C) to RAM and FK. Additionally, work in the Krammer laboratory was partially funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051, by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 (5384); and by anonymous donors. Work in the Chandran laboratory was partially supported by NIH grant R01AI132633.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Scientific Ethics Committee at Pontificia Universidad Catolica de ChileAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting the findings of this study are available within the article and its supplementary material. The raw data that support the findings of this study are available on request from the corresponding author.